South & Central America Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)

Description

List of Tables

The South & Central America vaccine adjuvants market was valued at US$ 100.04 million in 2022 and is expected to reach US$ 284.89 million by 2030; it is estimated to register a CAGR of 14.0% from 2022 to 2030 .

Advancements in Biotechnology and Immunology Fuel South & Central America Vaccine Adjuvants Market

The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.

South & Central America Vaccine Adjuvants Market Overview

The South & Central America vaccine adjuvant market has been segmented into Brazil, Argentina, and the Rest of South & Central America . According to the Public Library of Science (PLOS) report, the use of adjuvants in vaccines is a key strategy for increasing immunity among the Brazilian population. Manufacturing adjuvanted vaccines is considered preparedness for public health emergencies such as pandemics. Therefore, the Brazilian government supports the production of adjuvanted vaccines. For example, Brazilian-manufactured "Oil-in-Water Emulsions" have revealed effective and safe adjuvanted vaccines to induce immune responses toward influenza antigens. The production of an adjuvanted vaccine for influenza in Brazil is conducted by the Butantan Institute, a public Sao Paulo State Institution, and the industrial infrastructure is capable of producing both seasonal and pandemic influenza adjuvanted vaccines.

South & Central America Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Vaccine Adjuvants Market Segmentation

The South & Central America vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the South & Central America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the South & Central America vaccine adjuvants market share in 2022.

By type, the South & Central America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of South & Central America vaccine adjuvants market in 2022.

By country, the South & Central America vaccine adjuvants market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; GSK Plc; Novavax Inc; and Phibro Animal Health Corp are some of the leading companies operating in the South & Central America vaccine adjuvants market.

Product Code: BMIRE00031094

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America Vaccine Adjuvants Market - Key Market Dynamics

4.1 South & Central America Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
- 4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
- 4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunity
- 4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
- 4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -South & Central America Market Analysis

5.1 South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
5.2 South & Central America Vaccine Adjuvants Market Forecast and Analysis

6. South & Central America Vaccine Adjuvants Market Analysis - by Adjuvant Class

6.1 Overview
6.2 Mineral Salt Adjuvant
- 6.2.1 Overview
- 6.2.2 Mineral Salt Adjuvant: South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
- 6.3.1 Overview
- 6.3.2 Emulsion Adjuvant: South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
- 6.4.1 Overview
- 6.4.2 Liposome Adjuvant: South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America Vaccine Adjuvants Market Analysis - by Type

7.1 Human Vaccine Adjuvant
- 7.1.1 Overview
- 7.1.2 Human Vaccine Adjuvant: South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
- 7.2.1 Overview
- 7.2.2 Veterinary Vaccine Adjuvant: South & Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. South and Central America Vaccine Adjuvants Market -Country Analysis

8.1 South & Central America
- 8.1.1 South and Central America Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 8.1.1.1 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.1 Overview
    - 8.1.1.1.2 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.3 Brazil: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.1.4 Brazil: Vaccine Adjuvants Market Breakdown by Type
  - 8.1.1.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.1 Overview
    - 8.1.1.2.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.3 Argentina: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.2.4 Argentina: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.3 Rest of South and Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.1 Overview
    - 8.1.1.3.2 Rest of South and Central America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.3 Rest of South and Central America Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.3.4 Rest of South and Central America Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Vaccine Adjuvants Market
9.3 Organic Developments
- 9.3.1 Overview
9.4 Inorganic Developments
- 9.4.1 Overview

10. Company Profiles

10.1 GSK Plc
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 CSL Ltd
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Croda International Plc
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Novavax Inc
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Phibro Animal Health Corp
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments

11. Appendix

11.1 About The Insight Partners